Tolnaftate
| Evidence Level: N/A | Predicted Indications: 0 |
Table of Contents
- Tolnaftate
Tolnaftate: Known uses and market status in Australia
Summary
The TxGNN deep-learning model (score ≥ 0.99) produced candidates for Tolnaftate, but every candidate that can be traced to a source is already a known use. There is therefore currently no new predicted indication for this drug. The three known uses below come from relations recorded in the knowledge graph.
Quick overview
| Item | Content |
|---|---|
| New predicted indications | None (all traceable model candidates are known uses) |
| Known uses among model candidates | 3 |
| Evidence level | Not applicable |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
Known uses among the model’s candidates
Approved (supported by a licence or label)
| Indication | Source |
|---|---|
| none | none |
Related to an approved indication (same disease category)
| Indication | Approved category |
|---|---|
| none | none |
Relations recorded in the knowledge graph (no approval found)
| Indication |
|---|
| dermatophytosis of groin and perianal area |
| tinea pedis |
| tinea corporis |
Australia Market Information
| Licence | Product | Dosage form | Status |
|---|---|---|---|
| 4481W | Tinaderm | Spray aerosol 0.7 mg per g (0.07%), 100 | Valid |
Safety Considerations
Please refer to the TGA-approved Product Information (PI) for safety information. No drug interactions were identified in the data compiled for this report.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.